Denis Krakhotkin

Dr. Denis Krakhotkin

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2020 in Chronic Diseases and Translational Medicine
Verified
Journal Article
Open access
DKDenis Krakhotkin
Denis Krakhotkin
VCVolodymyr A. Chernylovskyi
Volodymyr A. Chernylovskyi
AMAlexandre Mottrie
Alexandre Mottrie
FGFrancesco Greco
Francesco Greco
RBRuslan A. Bugaev
Ruslan A. Bugaev
Peyronie’s disease (PD) is a benign, progressive fibrotic disorder characterized by scar or plaques within the tunica albuginea (TA) of the penis. This study provides new insights into the pathogenesis of PD based on data from different studies regarding the roles of cytokines, cell signaling pathways, biochemical mechanisms, genetic factors responsible for fibrogenesis. A growing body of literature has shown that PD is a chronically impaired, localized, wound healing process within the TA and the Smith space. It is caused by the influence of different pathological stimuli, most often the effects of mechanical stress during sexual intercourse in genetically sensitive individuals with unusual anatomical TA features, imbalanced matrix metalloproteinase/tissue inhibitor of metalloproteinase (MMP/TIMP), and suppressed antioxidant systems during chronic inflammation. Other intracellular signal cascades are activated during fibrosis along with low expression levels of their negative regulators and transforming growth factor-β1 signaling. The development of multikinase agents with minimal side effects that can block several signal cell pathways would significantly improve fibrosis in PD tissues by acting on common downstream mediators.

1 January 2019 in Therapeutic Advances in Urology
Verified
Journal Article
Open access
PDF file
DKDenis Krakhotkin
Denis Krakhotkin
VCVolodymyr A. Chernylovskyi
Volodymyr A. Chernylovskyi
EBEvgeny E. Bakurov
Evgeny E. Bakurov
JSJohann Sperl
Johann Sperl
Background: The aim of this work was to evaluate the influence of UPOINT-guided (Urinary, Psychosocial, Organ-specific, Infection, Neurologic/systemic, Tenderness of skeletal muscles) multimodal therapy in patients with chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS) on the dynamic values of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score. Patients and methods: In our study we investigated 110 patients aged 26–68 years with CP/CPPS. We performed digital rectal examination (DRE), pre- and post-massage test (PPMT) urine culture, urine analysis, transrectal ultrasound investigation of prostate, antibiotic susceptibility testing. We divided the patients into the intervention group and the control group which was followed up without any therapy. For the intervention group we offered multimodal therapy based on each predominated positive phenotype. For the urinary phenotype, patients in intervention group received 10 mg alfuzosin. For organ-specific and tenderness domains, the patients of the intervention group received 63 mg Cernilton and 1 g Quercetin. For infection control, the patients of the intervention group received antimicrobial agents according to the results of the post-massage urine culture, antibiotic susceptibility testing and a high level of contamination >105 colony-forming units (CFU)/ml. Microbiological assessment of PPMT urine culture was conducted with aerobic and anaerobic methods of cultivation Results: The 110 patients had an average age of 43.9 ± 11.1 years and a median duration of symptoms of 6.21 ± 1.8 months. Of these, 11 patients did not complete the trial and therefore in quantitative terms, the distribution of patients was as follows: 54 in the intervention group and 45 in the control group. The average total NIH-CPSI score before treatment was 29.8 ± 6.1 in both groups. The mean NIH-CPSI of the pain, urinary, and quality of life (QOL) subscores before treatment was 15.1 ± 3.0, 7.4 ± 1.4 and 8.1 ± 2.1, respectively in both groups. After 6 weeks the PPMT urine culture of patients of the intervention group showed the absence or low-level contamination of microorganisms. After conducting the treatment, the mean total NIH-CPSI score in the intervention and control groups was 13.9 ± 2.8 ( p = 0.025) and 29.8 ± 5.8 ( p = 0.18), respectively. The average NIH-CPSI pain subscore in the intervention and control group after treatment was 6.7 ± 1.4 ( p = 0.018) and 15.1 ± 2.8 ( p = 0.21), respectively. The mean NIH-CPSI urinary subscore after treatment in the intervention and control group was 3.22 ± 1.07 ( p = 0.045) and 7.4 ± 1.2 ( p = 0.15), respectively. The average NIH-CPSI QOL subscore after treatment in the intervention and control group was 3.87 ± 1.28 ( p = 0.015) and 8.1 ± 1.9 ( p = 0.35). After multimodal therapy, the prevalence of different UPOINT-positive domains in the patients of both intervention groups did not exceed 14%. Conclusions: The UPOINT clinical phenotypes significantly changed after multimodal treatment, including antibiotics, phytotherapy and α-blockers in patients with CP/CPPS. This combination of treatment showed a decreasing total NIH-CPSI score and an elevation of QOL in patients.

1 January 2017 in Urology Herald
Verified
Journal Article
Open access
PDF file
HIH. S. Ibishev
H. S. Ibishev
DKDenis Krakhotkin
Denis Krakhotkin
AVA. A. Vasiliev
A. A. Vasiliev
PKP. A. Krayniy
P. A. Krayniy
Введение. Рецидивирующая инфекция нижних мочевых путей (РИНМП) представляет собой актуальную проблему современной урологии. Цель исследования. Комплексное изучение инфекции мочевых путей, в том числе вирусной этиологии при хроническом рецидивирующем цистите у женщин. Материалы и методы. В исследование включены 31 женщин с РИНМП. Критерии включения: наличие симптомов инфекции нижних мочевых путей, тяжелое рецидивирующее течение, отсутствие анатомических и функциональных нарушений мочевых путей, бактериальных патогенов при культуральном исследовании с учетом аэробной и анаэробной методик культивирования. Результаты. При анализе клинических проявлений доминирующими в исследуемой группе были болевой синдром и императивные позывы к мочеиспусканию у 100% и 90% обследованных женщин соответственно, а учащенное мочеиспускание регистрировали реже - у 16,1% пациенток. При общеклиническом исследовании мочи во всех случаях выявлена лейкоцитурия и в 90% случаев - гематурия. С помощью полимеразной цепной реакции (ПЦР) в средней порции мочи у всех обследованных верифицировано 10 типов вирусов папилломы человека (ВПЧ) с доминированием 16 и 18 типов. Учитывая наличие рецидивирующего инфекционно-воспалительного процесса мочевых путей, всем пациенткам выполнялась цистоскопия с биопсией мочевого пузыря. При гистоморфологическом исследовании биоптатов у всех обследованных пациенток отмечено наличие специфических характеристик папилломавирусной инфекции (ПВИ): папиллярной сквамозной гиперплазии с койлоцитозом, светлой цитоплазмой и сморщенными ядрами. При анализе результатов ПЦР биопсийного материала данные корреспондировали с результатами ПЦР в средней порции мочи, во всех биоптатах был выявлен ВПЧ. Выводы. Папилломавирусная инфекция может быть причастна к развитию вирусного цистита. В этиологической структуре вирусного цистита могут выступать как высоко онкогенные, так и низко онкогенные типы ВПЧ.

1 March 2021 in Asian Journal of Andrology
Verified
Journal Article
Open access
DKDenis Krakhotkin
Denis Krakhotkin
DRDavid J Ralph
David J Ralph
GBGideon A Blecher
Gideon A Blecher
VCVolodymyr A Chernylovskyi
Volodymyr A Chernylovskyi
FGFrancesco Greco
Francesco Greco
RBRuslan A Bugaev
Ruslan A Bugaev
Residual penile curvature is a common situation following the implantation of a penile prosthesis in patients with Peyronie's disease. Currently, there is a variety of options for the correction of residual curvature, including penile modeling, plication techniques, as well as tunical incision/excision with or without grafting. A literature search of PubMed and Medline databases was conducted from 1964 until 2020, using search terms for all articles in the English language. In this article, we provide a review of the techniques and the outcomes, according to the published literature.

1 May 2018 in Urology Case Reports
Verified
Journal Article
Open access
PDF file
EBE.E. Bakurov
E.E. Bakurov
DKDenis Krakhotkin
Denis Krakhotkin
OKO.B. Kucherenko
O.B. Kucherenko

2 June 2022 in Journal of Obstetrics and Gynaecology
Verified
Journal Article
Closed access
DKDenis Krakhotkin
Denis Krakhotkin
MSMaria N. Silkina
Maria N. Silkina
VCVolodymyr A. Chernylovskyi
Volodymyr A. Chernylovskyi
SGSvetlana A. Gayvoronskaya
Svetlana A. Gayvoronskaya
The aim of the study was to examine the severity of clinical symptoms of acute cystitis and the level bacteriuria in female patients who underwent to laparoscopic surgery followed by a postoperative administration of dienogest 2 mg and combined oral contraceptives pills (COCP). One hundred and forty five women who had a laparoscopic surgery prospectively were enrolled. Criteria inclusions were the age from 30 to 45 years old; body mass index (BMI) absence of previous hormonal therapy at least 6 month and recent performed a laparoscopy surgery for endometriosis. The women (n = 35) who had uterine myoma, abnormal coagulation profile; concomitant neoplastic diseases; chronic pelvic inflammatory disease and chronic recurrent cystitis were excluded from study. The female patients were assigned into both groups treatment: group I (n = 54) and group II (control, n = 56) who received dienogest 2 mg once daily and COCP, respectively. During follow-up three female patients of group I were withdrawn due to prolonged genital bleedings. The final analysis included 105 women. The patients of both groups had a low level of bacteriuria <103 CFU/ml without clinical symptoms of acute cystitis before treatment. The level of bacteriuria in-group I significantly increased from 102 to 106 CFU/ml whereas in-group II did not exceed 102 CFU/ml during 4 weeks of hormonal treatment. The differences of values of acute cystitis symptom score (ACSS) for differential, typical, quality of life domains were statistically significant after 4, 8 and 12 weeks of therapy in-group I compared with group II. During 3 months of hormonal treatment with dienogest 2 mg in group I, the acute cystitis developed in 10 (18.5%), in 19 (38%) and in 34 (68%) women at 4, 8 and 12 weeks of follow-up, respectively. All cases of acute cystitis in-group I were successfully treated with fosfomycin trometamol 3 g single dose or nitrofurantoin 50 mg four times a day during 5 days. We concluded that the dienogest might increase the level bacteriuria and severity of clinical symptoms of acute cystitis during a postoperative prophylaxis of endometriosis.